MAIA Biotechnology Inc

AMEX:MAIA (USA)  
$ 3.54 -0.24 (-6.35%) 12:09 AM EST
At Loss
Market Cap:
$ 77.30M
Enterprise V:
$ 77.10M
Volume:
186.93K
Avg Vol (2M):
447.50K
Trade In:
Volume:
186.93K
At Loss
Avg Vol (2M):
447.50K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for MAIA Biotechnology Inc ( ) from 2022 to Jun 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. MAIA Biotechnology stock (MAIA) PE ratio as of Jun 19 2024 is 0. More Details

MAIA Biotechnology Inc (MAIA) PE Ratio (TTM) Chart

To

MAIA Biotechnology Inc (MAIA) PE Ratio (TTM) Historical Data

Total 477
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
MAIA Biotechnology PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-19 At Loss 2024-04-16 At Loss
2024-06-18 At Loss 2024-04-15 At Loss
2024-06-17 At Loss 2024-04-12 At Loss
2024-06-14 At Loss 2024-04-11 At Loss
2024-06-13 At Loss 2024-04-10 At Loss
2024-06-12 At Loss 2024-04-09 At Loss
2024-06-11 At Loss 2024-04-08 At Loss
2024-06-10 At Loss 2024-04-05 At Loss
2024-06-07 At Loss 2024-04-04 At Loss
2024-06-06 At Loss 2024-04-03 At Loss
2024-06-05 At Loss 2024-04-02 At Loss
2024-06-04 At Loss 2024-04-01 At Loss
2024-06-03 At Loss 2024-03-28 At Loss
2024-05-31 At Loss 2024-03-27 At Loss
2024-05-30 At Loss 2024-03-26 At Loss
2024-05-29 At Loss 2024-03-25 At Loss
2024-05-28 At Loss 2024-03-22 At Loss
2024-05-24 At Loss 2024-03-21 At Loss
2024-05-23 At Loss 2024-03-20 At Loss
2024-05-22 At Loss 2024-03-19 At Loss
2024-05-21 At Loss 2024-03-18 At Loss
2024-05-20 At Loss 2024-03-15 At Loss
2024-05-17 At Loss 2024-03-14 At Loss
2024-05-16 At Loss 2024-03-13 At Loss
2024-05-15 At Loss 2024-03-12 At Loss
2024-05-14 At Loss 2024-03-11 At Loss
2024-05-13 At Loss 2024-03-08 At Loss
2024-05-10 At Loss 2024-03-07 At Loss
2024-05-09 At Loss 2024-03-06 At Loss
2024-05-08 At Loss 2024-03-05 At Loss
2024-05-07 At Loss 2024-03-04 At Loss
2024-05-06 At Loss 2024-03-01 At Loss
2024-05-03 At Loss 2024-02-29 At Loss
2024-05-02 At Loss 2024-02-28 At Loss
2024-05-01 At Loss 2024-02-27 At Loss
2024-04-30 At Loss 2024-02-26 At Loss
2024-04-29 At Loss 2024-02-23 At Loss
2024-04-26 At Loss 2024-02-22 At Loss
2024-04-25 At Loss 2024-02-21 At Loss
2024-04-24 At Loss 2024-02-20 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss

MAIA Biotechnology Inc (MAIA) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.